PL2137202T3 - Sposób syntezy IB-MECA - Google Patents

Sposób syntezy IB-MECA

Info

Publication number
PL2137202T3
PL2137202T3 PL08719985T PL08719985T PL2137202T3 PL 2137202 T3 PL2137202 T3 PL 2137202T3 PL 08719985 T PL08719985 T PL 08719985T PL 08719985 T PL08719985 T PL 08719985T PL 2137202 T3 PL2137202 T3 PL 2137202T3
Authority
PL
Poland
Prior art keywords
meca
synthesis
Prior art date
Application number
PL08719985T
Other languages
English (en)
Inventor
Paul Bruzinski
Xuejun Liu
Cameron Gibb
Pedro Hernandez-Abad
Original Assignee
Can-Fite Biopharma Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Can-Fite Biopharma Ltd. filed Critical Can-Fite Biopharma Ltd.
Publication of PL2137202T3 publication Critical patent/PL2137202T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
PL08719985T 2007-03-14 2008-03-13 Sposób syntezy IB-MECA PL2137202T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90683807P 2007-03-14 2007-03-14
EP08719985.7A EP2137202B1 (en) 2007-03-14 2008-03-13 Process for the synthesis of ib-meca
PCT/IL2008/000360 WO2008111082A1 (en) 2007-03-14 2008-03-13 Process for the synthesis of ib-meca

Publications (1)

Publication Number Publication Date
PL2137202T3 true PL2137202T3 (pl) 2017-12-29

Family

ID=39530638

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08719985T PL2137202T3 (pl) 2007-03-14 2008-03-13 Sposób syntezy IB-MECA

Country Status (10)

Country Link
US (1) US9102698B2 (pl)
EP (1) EP2137202B1 (pl)
JP (1) JP5467872B2 (pl)
CN (1) CN101646685B (pl)
DK (1) DK2137202T3 (pl)
ES (1) ES2641190T3 (pl)
HU (1) HUE034474T2 (pl)
PL (1) PL2137202T3 (pl)
PT (1) PT2137202T (pl)
WO (1) WO2008111082A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019105388A1 (zh) * 2017-11-29 2019-06-06 苏州科睿思制药有限公司 一种a3腺苷受体激动剂药物的晶型及其制备方法和用途
CN110003211A (zh) * 2019-05-06 2019-07-12 江苏联昇化学有限公司 一种抗癌药物cf-102的合成新工艺
IT202300020286A1 (it) * 2023-10-02 2025-04-02 Procos Spa Processo per la sintesi di piclidenoson a partire dall’adenosina
CN121045296A (zh) * 2024-05-31 2025-12-02 康菲特生物制药有限公司 制备纳莫德诺森的工艺

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4930392A (pl) * 1972-07-18 1974-03-18
DE2244328A1 (de) 1972-09-09 1974-03-21 Boehringer Mannheim Gmbh Neue n(6)-disubstituierte adenosinderivate und verfahren zur herstellung derselben
AU7331094A (en) * 1993-07-13 1995-02-13 United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The A3 adenosine receptor agonists
IL127947A0 (en) 1999-01-07 1999-11-30 Can Fite Technologies Ltd Pharmaceutical use of adenosine agonists
CN1259056C (zh) 2001-01-16 2006-06-14 坎-菲特生物药物有限公司 腺苷a3受体激动剂用于抑制病毒复制的用途
ATE371191T1 (de) 2002-10-22 2007-09-15 Can Fite Biopharma Ltd Die verwendung von dem a3 adenosin rezeptor als marker eines krankheitszustandes
US7141553B2 (en) 2002-11-19 2006-11-28 Can-Fite Biopharma Ltd. Israel A3AR agonists for the treatment of inflammatory arthritis
JPWO2004065403A1 (ja) * 2003-01-17 2006-05-18 味の素株式会社 ヌクレオシド化合物の製造方法
FI115172B (fi) 2003-07-24 2005-03-15 Filtronic Lk Oy Antennijärjestely ulkoisen laitteen liittämiseksi radiolaitteeseen
PL1699459T3 (pl) 2003-12-29 2007-12-31 Can Fite Biopharma Ltd Sposób leczenia stwardnienia rozsianego
ES2432113T3 (es) 2004-07-28 2013-11-29 Can-Fite Biopharma Ltd. Agonistas del receptor de adenosina A3 para el tratamiento de trastornos del ojo seco, incluido el síndrome de Sjogren
US7825102B2 (en) * 2004-07-28 2010-11-02 Can-Fite Biopharma Ltd. Treatment of dry eye conditions
CA2586845A1 (en) 2004-11-08 2006-05-11 Can-Fite Biopharma Ltd. Therapeutic treatment of accelerated bone resorption
WO2006059327A1 (en) 2004-12-02 2006-06-08 Can-Fite Biopharma Ltd. A biological marker for inflammation
EP1959939B1 (en) 2005-11-30 2012-01-11 Can-Fite Biopharma Ltd. Use of a3 adenosine receptor agonist in osteoarthritis treatment
BRPI0621052A2 (pt) 2006-01-27 2012-07-17 Can Fite Biopharma Ltd uso de um agonista de receptor de adenosina a3 (a3ar)

Also Published As

Publication number Publication date
HUE034474T2 (en) 2018-02-28
EP2137202B1 (en) 2017-06-21
WO2008111082A1 (en) 2008-09-18
JP2010521452A (ja) 2010-06-24
US9102698B2 (en) 2015-08-11
US20100087636A1 (en) 2010-04-08
DK2137202T3 (en) 2017-10-02
EP2137202A1 (en) 2009-12-30
ES2641190T3 (es) 2017-11-08
PT2137202T (pt) 2017-10-02
CN101646685B (zh) 2014-12-17
CN101646685A (zh) 2010-02-10
JP5467872B2 (ja) 2014-04-09

Similar Documents

Publication Publication Date Title
ZA200905012B (en) Process for the preparation of certain substituted sulfimines
EP2212248A4 (en) PROCESS FOR THE PREPARATION OF GRAPHS
EG25753A (en) Process for the production of alcohols
IL202046A0 (en) Process for the manufacture of p4o6
PL2121577T3 (pl) Sposób syntezy kwasów omega-aminoalkanowych
GB0702854D0 (en) Method for the synthesis of sucrose-6-esters
EG25867A (en) Enhanced process for the synthesis of urea
IL201245A0 (en) An improved process for the synthesis of solifenacin
ZA201008222B (en) Process for the synthesis of arformoterol
IL220430A0 (en) Process for the production of benzopyran-2-ol derivatives
ZA200907191B (en) Process for the preparation of gefitiib
ZA200905335B (en) Process for the synthesis of agomelatine
IL196474A0 (en) Improved process for the preparation of voriconazole
HU0700818D0 (en) Process for the preparation of polyirocyanates of the diphenylmethone series
ZA201105709B (en) Process for the synthesis of cleistanthin
IL206530A0 (en) Process for the preparation of 6-substituted-1-(2h)-isoquinolinones
IL205082A0 (en) Process for the preparation of tetranorlabdane derivatives
ZA200905051B (en) Process for the synthesis of agomelatine
PL2137202T3 (pl) Sposób syntezy IB-MECA
ZA200806049B (en) Cefdinir synthesis process
GB2464854B (en) Process for the preparation of risperidone
HUP0700461A2 (en) Process for producing 9alpha-hydroxy-steroids
GB2459413B (en) Methods for the synthesis of perfluoroparacyclophane
ZA201104657B (en) Synthesis of morphine-6-glucuronide or one of the derivatives thereof
IL194330A0 (en) Processes for the synthesis of 3-isobutylglutaric acid